Publications by authors named "P Hadji"

Claim this Profile
P
Prognostic impact of the choice of chemotherapy after first-line CDK4/6 inhibitor therapy in patients with metastatic hormone receptor-positive, HER2-negative breast cancer.
Laura L Michel, Philipp Ziegler, Philipp Kreis, Andreas D Hartkopf, Markus Wallwiener, Peyman Hadji

Eur J Cancer· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Biosimilars in osteoporosis treatment: focus on denosumab.
Matti Aapro, Peyman Hadji, Daniele Santini, Ralf Schmidmaier, Richard Eastell

Expert Opin Biol Ther· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Management of aromatase inhibitor-associated bone loss (AIBL) in women with hormone-sensitive breast cancer: An updated joint position statement of the IOF, CABS, ECTS, IEG, ESCEO, IMS, and SIOG.
Peyman Hadji, Matty Aapro, Nasser Al-Dagri, Majed Alokail, Emmanuel Biver

J Bone Oncol· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effect of A Patient Reminder Program on Adherence in Postmenopausal Women with Osteoporosis Receiving Oral Bisphosphonate Treatment: A Randomized Clinical Control Trial.
U Stumpf, I Kyvernitakis, K Horas, P Hadji

Calcif Tissue Int· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Bone Effects of Anti-Cancer Treatments in 2024.
Marie Teissonnière, Mathieu Point, Emmanuel Biver, Peyman Hadji, Edith Bonnelye

Calcif Tissue Int· March 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis